Valuation of Equity in Access to Alzheimer's Treatments

Last registered on March 06, 2024
View Trial History

Pre-Trial

Trial Information

General Information

Title
Valuation of Equity in Access to Alzheimer's Treatments
RCT ID
AEARCTR-0012931
Initial registration date
February 20, 2024

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
March 06, 2024, 3:03 PM EST

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Primary Investigator

Name
Jeremy Burke
Affiliation
University of Southern California, Center for Economic and Social Research
Contact Primary Investigator

Other Primary Investigator(s)

PI Name
Francisco Perez-Arce
PI Affiliation
University of Southern California, Center for Economic and Social Research
Contact Investigator
PI Name
Soeren Mattke
PI Affiliation
University of Southern California, Center for Economic and Social Research
Contact Investigator

Additional Trial Information

Status
In development
Start date
2024-04-01
End date
2024-07-01
Keywords
Health, Lab
Additional Keywords
Alzheimer's
JEL code(s)
Secondary IDs
Prior work
This trial does not extend or rely on any prior RCTs.
Abstract
This study will conduct an online experiment to examine how much Americans may be willing to pay for improved equity in health outcomes. Participants will receive a description of a hypothetical Alzheimer's disease treatment that reduces disease progression, but is not covered by insurance, and ask respondents whether they would (hypothetically) be willing to pay various amounts to make it available for everyone using unfolding valuation brackets. We will present the choice using three different frames, randomized across participants: (1) a neutral frame, and frames highlighting Alzheimer's disease's disproportionate effects on (2) individuals with low socioeconomic status, and (3) persons of color. Comparing valuations across groups will provide an estimate of the incremental valuation of the equity-enhancing properties of the treatment and capture whether the valuation differs if inequality is framed in economic or racial/ethnic terms.
External Link(s)

Registration Citation

Citation
Burke, Jeremy, Soeren Mattke and Francisco Perez-Arce. 2024. "Valuation of Equity in Access to Alzheimer's Treatments." AEA RCT Registry. March 06. https://doi.org/10.1257/rct.12931-1.0
Sponsors & Partners
Experimental Details

Interventions

Intervention(s)
The intervention will vary the description of the population burden of Alzheimer's disease. Condition (1) will describe the incidence rate for the overall population. Conditions (2) and (3) will be identical to condition (1), yet will also note the higher incidence among (2) low socioeconomic individuals, and (3) people of color, respectively.
Intervention Start Date
2024-04-01
Intervention End Date
2024-05-01

Primary Outcomes

Primary Outcomes (end points)
Willingness to pay for the hypothetical treatment
Primary Outcomes (explanation)

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
Survey participants will be randomized into one of three conditions (with equal probability), varying the description of the population burden of Alzheimer's disease. Condition (1) will describe the incidence rate for the overall population. Conditions (2) and (3) will be identical to condition (1), yet will also note the higher incidence among (2) low socioeconomic individuals, and (3) people of color, respectively.
Experimental Design Details
Not available
Randomization Method
Randomization done by a computer during online survey administration
Randomization Unit
Individual
Was the treatment clustered?
No

Experiment Characteristics

Sample size: planned number of clusters
4,500
Sample size: planned number of observations
4,500
Sample size (or number of clusters) by treatment arms
1,500
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
Supporting Documents and Materials
IRB

Institutional Review Boards (IRBs)

IRB Name
BRANY
IRB Approval Date
2023-12-18
IRB Approval Number
22-030-1044
Analysis Plan

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information